Three domestic pharmaceutical companies are leading the 10 billion market of psychotranquilizers, and 12 class 1 new drugs are under development

On May 25, Enhua pharmaceutical released a notice that the company's chemical product class 1, zilonapine succinate tablet and its API have received CFDA's notice on acceptance of clinical trials of new drug applications Zilonapine Succinate Tablets are mainly used in the treatment of acute and chronic schizophrenia, as well as other kinds of psychotic state According to the latest data of minenet, in 2017, the market scale of terminal chemical psychostatic drugs in public medical institutions in China exceeded 12.5 billion yuan On May 29, Enhua Pharmaceutical Co., Ltd announced again that another nervous system drug of the company, pregabalin sustained-release capsule (chemical 2.2), was approved for clinical use The clinical indications applied for were for the treatment of postherpetic neuralgia Enhua Pharmaceutical Co., Ltd has successively launched new products in the field of central nervous drugs, and its market position is also constantly improving   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> 10 billion market of psychotranquilizers, with hausen, Hengrui and Enhua accounting for four components Table 1: market share of top 3 enterprises of terminal chemical psychotranquilizers in China's public medical institutions (source: minenet China's public medical institutions terminal competition pattern) According to the data of MI nei.com, the top 3 enterprises in the market of terminal chemical psychostatic drugs in China's urban public hospitals, county-level public hospitals, urban communities and township health centers (referred to as China's public medical institutions) are Jiangsu Haosen Pharmaceutical Group, Jiangsu Hengrui pharmaceutical and Jiangsu Enhua pharmaceutical respectively, and the three domestic pharmaceutical enterprises have taken over 40% of the market share in total In the past five years, the market share of Howson pharmaceutical industry has declined The market share of Hengrui pharmaceutical has increased rapidly, while that of Enhua pharmaceutical industry has increased steadily Table 2: ranking and sales of three enterprises in the top 20 brands of terminal chemical drugs and psychotropic drugs in China's public medical institutions (unit: 10000 yuan) (source: minenet China's public medical institutions terminal competition pattern) In 2017, among the top 20 brands of terminal chemical drugs and psychotropic drugs in China's public medical institutions, olanzapine tablets of hausen Pharmaceutical Co., Ltd ranked first, with sales up to 2.4 billion yuan Henri pharmaceutical's dexmedetomidine hydrochloride injection ranked second, and its sales volume has also entered the echelon of 2 billion yuan since 2017 Enhua Pharmaceutical Co., Ltd has two products in the top 20 list, which are midazolam injection ranked seventh and dexmedetomidine hydrochloride injection ranked 17th The sales of both products are over 100 million yuan, of which dexmedetomidine hydrochloride injection has a strong growth rate, with an increase rate of 235.54%, 253.47%, 34.88% and 73.55% in the last four years   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> specializing in central nervous products, Enhua pharmaceutical ranks top in three sub categories Table 3: Enhua pharmaceutical's ranking in all sub categories of terminal chemical drugs and nervous system drugs of public medical institutions in China in 2017 (source: minernet China public medical institutions terminal competition pattern) Enhua pharmaceutical is mainly engaged in the production of central nervous products, including the production and manufacturing of anesthesia, spirit and nerve pharmaceutical raw materials and preparations According to data from minenet, in addition to ranking first in the market of psychotropic drugs, Enhua pharmaceutical also ranks eighth and ninth in the sub market of anesthetics and antiepileptics in nervous system drugs Midazolam injection is mainly used for pre anesthesia administration, induction and maintenance of general anesthesia, and sedation of ICU patients In 2017, it ranked seventh in the top 20 brand of terminal chemical psychostatic in China's public medical institutions; dexmedetomidine hydrochloride injection Sedation during tracheal intubation and mechanical ventilation is mainly used for general anesthesia of surgical patients In 2017, it ranked 17th in the top 20 brand of terminal chemical antipsychotic drugs in China's public medical institutions At present, Hengrui pharmaceutical and Sichuan Guorui pharmaceutical are the competitors of this product in the market Etomidate emulsion injection and etomidate injection are mainly used for induction of general anesthesia and also for short-term surgery anesthesia In 2017, etomidate emulsion injection and etomidate injection ranked 12th and 16th respectively in the top 20 brands of terminal chemical drugs and anesthetics in Chinese public medical institutions At present, the competitive enterprise of etomidate emulsion injection in the market is Braun, while the competitive enterprise of etomidate injection is Hengrui medicine Gabapentin capsule is mainly used for the treatment of adult postherpetic neuralgia and epilepsy adjuvant treatment In 2017, it ranked 13th in the top 20 brands of terminal chemical antiepileptic drugs in China's public medical institutions At present, Hengrui medicine is the competitive enterprise of this product in the market According to the annual report, Enhua pharmaceutical also has more than 30 APIs, such as midazolam maleate, etomidate, dexmedetomidine hydrochloride, risperidone, fenofibrate powder, citalopram hydrobromide, gabapentin, and pentafluridol, which are used in the company's preparation production and sales at home and abroad In 2017, the operating revenue of Enhua pharmaceutical industry was 3.394 billion yuan, with the total operating revenue of psychotropic drugs, anesthetics and antiepileptics accounting for nearly 50% of the company's total revenue, API accounting for 1.8% and pharmaceutical business accounting for 43.6%   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> from 2017 to now, 12 approved clinical class 1 new drugs are available Table 4: the situation of some approved clinical class 1 new drugs in research (source: med2.0 database of minenet, statistics as of June 7, 2018, statistical scope: products in the field of treatment) kl100137 fat emulsion injection It is a new type of GABAA receptor agonist independently developed by Kelun Pharmaceutical Co., Ltd It belongs to intravenous anesthetics and is intended to be used in anesthesia induction, anesthesia maintenance, sedation during / after anesthesia and ICU ward, as well as outpatient anesthesia such as induced abortion, plastic surgery and various endoscopy Flunorpiperazil is a new drug of anti Alzheimer's disease It has not only high bioavailability, but also good brain targeting At the same time, its safety is far higher than that of donepezil, which is a first-line drug on the market It has a larger safety window and is expected to overcome the side effects of current clinical use of acetylcholinesterase inhibitors The product was developed by Shanghai Pharmaceutical Research Institute of Chinese Academy of Sciences, and a cooperation agreement was reached with Kangyuan pharmaceutical industry to transfer the achievements Shr8554 injection is a small molecule opioid receptor μ subtype (MOR) preferred ligand, which is intended to be used in the treatment of pain At present, oliveridine (trv130) developed by Trevena company is a similar product under research in foreign countries, which is currently in phase III clinical research stage in the United States Morphine-6-glucuronide injection is a kind of opioid analgesic, which can be used in the treatment of moderate to severe pain Compared with morphine preparation, the product has stronger analgesic activity, longer maintenance time, better tolerance, and can effectively improve adverse reactions such as nausea, vomiting, respiratory inhibition, etc The indication of hec30654acoh capsule is Alzheimer's disease Wx0005 tablet is a drug jointly developed by the technical center of Harbin Pharmaceutical Group and yaomingkant The new drug is intended to be applied to epilepsy The target of the new drug is sodium channel and pde1 double target It can not only prevent epilepsy, but also improve brain damage caused by epilepsy Tirirafon for injection is a class 1 new drug of Nanjing Zhongrui Pharmaceutical Co., Ltd., which is used for emergency treatment of stroke Some studies have pointed out that the efficacy of tirirafon is twice that of edaravone, and the sales potential of tirirafon is predicted to reach 2 billion in the future It is reported that edaravone has become the first choice of routine emergency medicine for stroke patients in the year of edaravone The active component of spt-07a injection is a small molecule monomer compound extracted from natural medicine, which has certain clinical basis of safety and effectiveness The injection is used in the neuroprotective treatment of acute ischemic stroke (stroke) Tpn672 maleate is a new anti schizophrenia drug It has a two-way regulatory effect on dopamine receptor, and also acts on 5-hydroxytryptamine receptor and 5-hydroxytryptamine transporter, so as to balance and regulate the function of central nervous system Shanghai Pharmaceutical Research Institute has signed a cooperation agreement with Kangyuan pharmaceutical to carry out clinical research The left-handed hydrochloric acid demethylphenacyronyl ester tablet has a better therapeutic effect on the tremor symptoms of the patients with early Parkinson's disease (S) - oxiracetam tablet, (s) - oxiracetam capsule is the left-handed body of oxiracetam, which can promote ATP in the brain, promote the synthesis of acetylcholine and enhance the conduction of nerve excitation, improve the retrograde amnesia caused by hypoxia, enhance memory and improve learning ability Source: public announcement of listed companies, Internet Database